Altamira Therapeutics (CYTOF)
OTHER OTC:CYTOF
Top Page
No summary available
Positive Factors
Equity Improvement
The improvement in equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future growth initiatives.
Negative Factors
Negative Cash Flow
Persistent negative cash flow can strain the company's liquidity, limiting its ability to invest in growth opportunities and potentially necessitating additional funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Equity Improvement
The improvement in equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future growth initiatives.
Read all positive factors
Altamira Therapeutics (CYTOF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$286.92K
Dividend YieldN/A
Average Volume (3M)8.02K
Price to Earnings (P/E)―
Beta (1Y)2.11
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,715,472
10 Day Avg. Volume7,440
30 Day Avg. Volume8,018
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap3.96
Enterprise Value/Revenue-3.22
Enterprise Value/Gross Profit-1.65
Enterprise Value/Ebitda0.56
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.61
Revenue Forecast (FY)$5.15M
Altamira Therapeutics Business Overview & Revenue Model
Company Description
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertig...
How the Company Makes Money
Altamira Therapeutics primarily generates revenue through the development and commercialization of its RNA-based therapeutic products. The company may earn income from licensing agreements, partnerships, and collaborations with other pharmaceutica...
Altamira Therapeutics Earnings Call Summary
Earnings Call Date:Apr 30, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Sep 09, 2026
Earnings Call Sentiment Neutral
Altamira showed significant progress in its RNA delivery business with new partnerships and patent filings, while overcoming setbacks such as Nasdaq delisting and increased net loss. The strategy to involve private equity investors and spin-off RNA delivery activities indicates proactive steps for future growth.Positive Updates
RNA Delivery Business Momentum
Altamira gained 2 new partners for its xPhore platform and demonstrated its versatility with circular RNA, opening new business opportunities.
Negative Updates
Nasdaq Delisting
Nasdaq delisted Altamira's common shares due to a minimum bid price issue, impacting funding from public markets.
Read all updates
Q4-2024 Updates
Positive
Negative
RNA Delivery Business Momentum
Altamira gained 2 new partners for its xPhore platform and demonstrated its versatility with circular RNA, opening new business opportunities.
Read all positive updates
Company Guidance
During the Altamira Therapeutics' full-year 2024 financial results and business update call, the company provided several key metrics and strategic insights. The operating loss from continuing operations increased slightly from $6.6 million in 2023 to $6.9 million in 2024. Research and development expenses rose to $3.7 million from $3.4 million the previous year, whereas general and administrative expenses decreased to $3.2 million from $3.5 million. Notably, net finance expenses dropped significantly from $1.5 million to $0.8 million. The net loss for 2024 was reported at $8.5 million, with a cash usage reduction in operations from $12.8 million in 2023 to $6.1 million in 2024. Cash and cash equivalents increased to $1 million by year-end. The company anticipates a reduction in operating expenses following the partial spin-off of its RNA delivery subsidiary, ATAG, and seeks to fund future operations through existing cash, private equity, and strategic partnerships.Altamira Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -353.22K | 0.00 | 305.62K | 63.88K | 174.47K | -56.00K |
| Gross Profit | -691.22K | 0.00 | -1.14M | -2.18M | 174.47K | -56.00K |
| EBITDA | 2.02M | -1.35M | -17.64M | -6.72M | -5.26M | -7.24M |
| Net Income | -15.83M | -7.27M | -26.53M | -17.39M | -8.20M | -6.63M |
Balance Sheet | ||||||
| Total Assets | 6.20M | 7.69M | 6.30M | 18.84M | 20.80M | 9.23M |
| Cash, Cash Equivalents and Short-Term Investments | 49.57K | 617.41K | 15.39K | 984.19K | 11.26M | 1.38M |
| Total Debt | 3.47M | 99.66K | 6.33M | 575.74K | 523.92K | 0.00 |
| Total Liabilities | 8.03M | 1.24M | 14.62M | 6.13M | 4.03M | 3.19M |
| Stockholders Equity | -1.82M | 6.46M | -8.31M | 12.70M | 16.77M | 6.04M |
Cash Flow | ||||||
| Free Cash Flow | -10.81M | -11.51M | -10.83M | -17.00M | -7.16M | -11.41M |
| Operating Cash Flow | -10.81M | -11.51M | -8.68M | -13.67M | -4.84M | -8.39M |
| Investing Cash Flow | -608.03K | 1.44M | -2.14M | -3.51M | -2.31M | -3.00M |
| Financing Cash Flow | 10.99M | 10.62M | 9.83M | 6.61M | 16.96M | 7.38M |
Altamira Therapeutics Technical Analysis
Negative
0.05
Price Trends
0.09
Negative
0.09
Negative
0.08
Negative
Market Momentum
-0.01
Positive
31.29
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTOF, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.09, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 31.29 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYTOF.
Altamira Therapeutics Risk Analysis
Altamira Therapeutics disclosed 41 risk factors in its most recent earnings report. Altamira Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Altamira Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $286.92K | -0.04 | -108.79% | ― | ― | ― | |
44 Neutral | $2.01M | ― | ― | ― | 178.82% | -4121.10% | |
43 Neutral | $1.59M | -0.07 | -63.03% | ― | -100.00% | 86.75% | |
| ― | $2.60M | -0.17 | -168.95% | ― | ― | 90.27% |
* Healthcare Sector Average
CYTOF
Altamira Therapeutics
0.05
-0.04
-43.82%
BDRX
Biodexa Pharmaceuticals
3.51
-71.99
-95.35%
QCLS
Q/C Technologies
3.61
-21.54
-85.65%
SCNI
Scinai Immunotherapeutics
0.58
-1.67
-74.22%
OGEN
Oragenics
0.60
-5.10
-89.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―